AMRx AMRX アムニ―ル・ファ―マシュ―ティカルズ

 AMRXのチャート


 AMRXの企業情報

symbol AMRx
会社名 Amneal Pharmaceuticals Inc (AMRX アムニ―ル・ファ―マシュ―ティカルズ)
分野(sector)   
産業(industry)   
業種 医薬品   医療関連(Health Care)
概要 事業概要 アムニール・ファーマシューティカルズ(Amneal Pharmaceuticals Inc.)は専門医薬会社である。同社は、ブランド製品の開発・マーケティング、及び生物学的同等医薬品(ジェネリック医薬品)の開発・製造・販売に従事する。同社は2つの事業セグメントを運営する。Impaxジェネリックスは、ブランド名の医薬品医薬品および治療剤と同等の薬品名で販売されている同社のジェネリック医薬品の開発・製造・販売・流通に従事する。Impax専門製薬事業は、パーキンソン病(PD)、脳炎後パーキンソニズムおよびパーキンソニズムの治療用カルビドパ - レボドパの持続放出経口カプセル製剤であるRytary等のブランド医薬品、並びに片頭痛の治療に適応されたゾミグ(ゾルミトリプタン)製品を含む複数のブランド製品の宣伝・販売・流通に従事する。  インパックス・ラボラトリ―ズは、米国の製薬会社。ジェネリック医薬品の開発、製造、販売、流通を中心に行うほか、片頭痛、多発性硬化症、パ―キンソン病、帯状疱疹後の神経痛など中枢神経系障害の治療のため自社ブランド医薬品の開発を手掛ける。主要製品は「Adderall XR」、「Trilipix」、「RYTARY」など。  
本社所在地 908 947-3120
代表者氏名 Paul M. Bisaro
代表者役職名 Executive Chairman of the Board
電話番号 +1 908-409-6700
設立年月日 34060
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 6000人
url www.amneal.com
nasdaq_url
adr_tso
EBITDA EBITDA(百万ドル) 373.66200
終値(lastsale)
時価総額(marketcap)
時価総額 時価総額(百万ドル) 4233.95800
売上高 売上高(百万ドル) 1662.99100
企業価値(EV) 企業価値(EV)(百万ドル) 6711.96000
当期純利益 当期純利益(百万ドル) -21.12000
決算概要 決算概要 BRIEF: For the fiscal year ended 31 December 2018 Amneal Pharmaceuticals Inc revenues increased from $775.8M to $1.66B. Net loss applicable to common stockholders excluding extraordinary items decreased 96% to $21.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects In-process research and development impa decrease of 80% to $39.3M (expense).

 AMRXのテクニカル分析


 AMRXのニュース

   The Daily Biotech Pulse: MediciNova Bags BARDA Contract, Lilly's COVID-19 Antibody Cocktail Data, Bluebird Bio Refutes Blood Cancer Link  2021/03/10 12:25:58 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 9) Amneal Pharmaceuticals, Inc. (NYSE: AMRX ) AngioDynamics, Inc. (NASDAQ: ANGO ) AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC ) ( announced a new-gen multi-cancer detection sensor) Axonics Modulation Technologies, Inc. (NASDAQ: AXNX ) Bausch Health Companies Inc. (NYSE: BHC ) (issued a pipeline update at a conference) Bolt Biotherapeutics, Inc. (NASDAQ: BOLT ) Cullinan Oncology, Inc. (NASDAQ: CGEM ) Five Prime Therapeutics, Inc. (NASDAQ: FPRX ) IDEAYA Biosciences, Inc. (NASDAQ: IDYA ) Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS ) (reacted to its fourth-quarter results) Second Sight Medical Products, Inc. (NASDAQ: EYES ) Silverback Therapeutics, Inc. (NASDAQ: SBTX ) Surmodics, Inc. (NASDAQ: SRDX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 9) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) (moved lower in reaction to FDA communication regarding deficiencies in its regulatory application for dementia drug) Immunocore Holdings plc (NASDAQ: IMCR ) Stocks In Focus MediciNova Gets BARDA Contract to Study MN-166 For Chlorine Gas-induced Lung Damage MediciNova, Inc. (NASDAQ: MNOV ) said it has partnered with the BARDA to repurpose MN-166 as a potential medical countermeasure against chlorine gas-induced lung damage such as acute respiratory distress syndrome and acute lung injury.
   Amneal Pharmaceuticals, Inc. to Host Earnings Call  2021/02/26 11:30:00 Yahoo Finance
NEW YORK, NY / ACCESSWIRE / February 26, 2021 / Amneal Pharmaceuticals, Inc. (NYSE:AMRX) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 26, 2021 at 8:30 AM Eastern Time.
   Amneal Receives Approval for Generic Version of Ortho Evra®  2021/02/26 11:02:00 Business Wire
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for 150 mcg/day Norelgestromin and 35 mcg/day Ethinyl Estradiol Transdermal System. In conjunction with its approval, Amneal received a Competitive Generic Therapy (CGT) designation by the FDA and has been granted 180 days of exclusivity. Amneal’s Norelgestr
   Amneal Reports Fourth Quarter and Full Year 2020 Financial Results  2021/02/26 11:00:00 Business Wire
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the "Company") announced its results today for the fourth quarter and full year ended December 31, 2020. "We are extremely proud of the progress our company has made since we re-joined as leaders of Amneal," said Chirag and Chintu Patel, Co-Chief Executive Officers. "In just a year and a half, we have made significant strides towards strategically positioning Amneal, both operationally and financially, for the next p
   Amneal to Virtually Participate at Upcoming Investor Conferences  2021/02/22 21:05:00 Business Wire
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that its management team will virtually attend the following investor conferences: Raymond James Institutional Investors Conference March 1, 2021 Fireside Chat – 3:00 p.m. Eastern Time Barclays Global Healthcare Conference March 10, 2021 Fireside Chat – 4:10 p.m. Eastern Time A live webcast of the presentations will be accessible through the Investor Relations section of the Company's w
   Amneal Pharmaceuticals, Inc. to Host Earnings Call  2021/02/26 11:30:00 Yahoo Finance
NEW YORK, NY / ACCESSWIRE / February 26, 2021 / Amneal Pharmaceuticals, Inc. (NYSE:AMRX) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 26, 2021 at 8:30 AM Eastern Time.
   Amneal Receives Approval for Generic Version of Ortho Evra®  2021/02/26 11:02:00 Business Wire
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for 150 mcg/day Norelgestromin and 35 mcg/day Ethinyl Estradiol Transdermal System. In conjunction with its approval, Amneal received a Competitive Generic Therapy (CGT) designation by the FDA and has been granted 180 days of exclusivity. Amneal’s Norelgestr
   Amneal Reports Fourth Quarter and Full Year 2020 Financial Results  2021/02/26 11:00:00 Business Wire
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the "Company") announced its results today for the fourth quarter and full year ended December 31, 2020. "We are extremely proud of the progress our company has made since we re-joined as leaders of Amneal," said Chirag and Chintu Patel, Co-Chief Executive Officers. "In just a year and a half, we have made significant strides towards strategically positioning Amneal, both operationally and financially, for the next p
   Amneal to Virtually Participate at Upcoming Investor Conferences  2021/02/22 21:05:00 Business Wire
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that its management team will virtually attend the following investor conferences: Raymond James Institutional Investors Conference March 1, 2021 Fireside Chat – 3:00 p.m. Eastern Time Barclays Global Healthcare Conference March 10, 2021 Fireside Chat – 4:10 p.m. Eastern Time A live webcast of the presentations will be accessible through the Investor Relations section of the Company's w
   Amneal to Report Fourth Quarter & Full Year 2020 Results on February 26, 2021  2021/02/04 13:00:00 Business Wire
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its fourth quarter and full year 2020 financial results on Friday, February 26, 2021, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on February 26, 2021. The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https:/
   Amneal to Report Fourth Quarter & Full Year 2020 Results on February 26, 2021  2021/02/04 13:00:00 Business Wire
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its fourth quarter and full year 2020 financial results on Friday, February 26, 2021, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on February 26, 2021. The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https:/
   Amneal to Acquire Substantially All of Kashiv Specialty Pharmaceuticals  2021/01/12 11:00:00 Business Wire
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (the “Company”) (NYSE:AMRX) and Kashiv BioSciences LLC (“Kashiv”) today announced they have entered into a definitive agreement under which Amneal Pharmaceuticals LLC (“Amneal”), a wholly-owned subsidiary of the Company, will acquire a 98% interest in Kashiv Specialty Pharmaceuticals, LLC (“Kashiv Specialty”), a wholly-owned subsidiary of Kashiv focused on the development of complex generics, innovative drug delivery platforms and
   Amneal Launches Generic Abiraterone Acetate Tablets, USP, 500 mg, Following ANDA Approval by FDA  2021/01/08 13:00:00 Business Wire
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced that it has received approval of an additional strength of 500 mg to its Abbreviated New Drug Application (ANDA), from the U.S. Food and Drug Administration (FDA) for Abiraterone Acetate Tablets, USP, 250 mg and 500 mg. This ANDA is approved for its use in combination with Prednisone. Abiraterone Acetate Tablets, USP, 250 mg and 500 mg, are the generic version of Zytiga® for treat
   Amneal to Virtually Participate at the 39th Annual J.P. Morgan Healthcare Conference  2021/01/05 14:23:00 Business Wire
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Amneal’s Co-Chief Executive Officer and President, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021 at 2:50 PM Eastern Time. A live webcast of the presentation will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com. A replay of the webcast will be posted shortly after the
   Global Narcolepsy Treatment Market Research Insights, COVID-19 Impact and Future Trends By 2026||Top Leaders-BIOPROJET, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Teva Pharmaceutical Industries  2020/12/29 18:50:43 OpenPR
The Narcolepsy Treatment market report is a window to the industry which explains what market definition, classifications, applications, engagements and market trends are. This study also analyzes the market status, growth rate, future trends, market drivers, opportunities and challenges, risks

 関連キーワード  (医薬品 米国株 AMRX アムニ―ル・ファ―マシュ―ティカルズ AMRX )

 twitter  (公式ツイッターやCEOツイッターなど)